-
IMPORTANT: In the next few weeks, we will be upgrading the message board software. We expect minimal downtime during the upgrade, and we will attempt to complete this during low-traffic hours. We will post an exact time several days ahead of the switch.Dismiss Notice
In preparation for the upgrade, we will be performing board maintenance, such as moving boards to Lost Civilizations where appropriate. Lost Civilizations is a category for companies that have either been dissolved or acquired. The boards serve as both an archive of the old company posts, as well as a place for former employees to reminisce or reconnect, as they will remain open for posting. We may also remove some board threads that have been inactive for several years.
Recent Posts
-
Phathom
Thats what happens when you latch yourself on to a sinking ship. Now they are looting us to keep themselves from drowning after over a decade of bad decisions. We obviously didnt have a choice as it pertains to vonoprazan, but still a good life...
-
WHC reorganization is here!
What’s funny is I like DSO so far but I think if Bill Anderson REALLY looked at what was happening on the Pharma side of things he would realize PB is not the leader to take us forward. BA is too busy (rightfully so) trying to save Crop Science...
-
Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B
via Biogen will make an upfront payment of $1.15 billion to HI-Bio and the latter’s stockholders will be eligible for payments of up to an additional $650 million. article source
-
Bristol Myers lines up Opdivo treatment in Pakistan, Rwanda and beyond as part of 10-year...
via When it comes to supporting cancer care and other therapeutic approaches in low- and middle-income countries (LMICs), Bristol Myers Squibb is taking a long-term view. In its quest to reach more than 200,000 patients with its medicines in...
-
FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin
via The U.S. Food and Drug Administration's staff said on Wednesday the use of Novo Nordisk's (NOVOb.CO) long-acting weekly insulin had an increased risk of low blood sugar in patients with type 1 diabetes, who are more insulin-dependent....
-
J&J Positions Tremfya as Stelara Successor with Strong Head-to-Head Data
via Johnson & Johnson on Tuesday unveiled early Phase II/III data from its GALAXI 2 and GLAXI 3 studies, showing that its IL-23 blocker Tremfya (guselkumab) outperformed its blockbuster antibody Stelara (ustekinumab) in the treatment of...
-
Boehringer pays OSE $42M to expand collab into cardio disease, grab new asset
via Boehringer Ingelheim is handing over a total of 38.8 million euros ($42 million) to long-time partner OSE Immunotherapeutics for a preclinical anti-PD1/cytokine drug as well as to expand their existing solid tumor work into...
- + Show More
-
General Discussion
Discussion boards of general interest for those in the pharma, biotech, medical device, and related industries
-
Pharma/Biotech Companies
Anonymous discussion boards for pharmaceutical and biotech companies
-
Regional Discussion and Job Opportunities
Discussion and job opportunities by region
-
Lost Civilizations
Anonymous discussion boards for pharma/medical companies that no longer exist due to acquisition or other factors
-
Laboratory/Diagnostic Sales
Anonymous discussion boards for lab sales/diagnostics companies
-
Animal Health Sales
Anonymous discussion boards for animal health companies
-
Medical Equipment/Device Sales
Anonymous discussion boards for medical equipment/device companies
-
Pharmacies
Anonymous boards for pharmacy employees
-
PBMs
Anonymous discussion boards for PBMs
-
Pharma/Healthcare Marketing Agencies
Anonymous discussion boards for pharma/healthcare marketing agencies
-
Dental Reps
Anonymous discussion boards for dental health companies
-
Managed Care Specialists
Anonymous discussion boards for managed care specialists
-
Pharma IT
Anonymous discussion boards for pharma IT employees